Fujifilm Diosynth Biotechnologies appoints Christine Vannais COO of North Carolina site

17 Mar 2020

Fujifilm Diosynth Biotechnologies has appointed Christine Vannais as chief operating officer at its North Carolina site, the biologics focused CDMO said Monday.

Vannais joined FDB in 2012 and has led the North Carolina manufacturing operations team since 2014. In this role, she was responsible for the site’s 24/7 manufacturing operations, including cGMP production in both microbial and mammalian systems.

Fujifilm Diosynth Biotechnologies appoints Christine Vannais COO of North Carolina site

Incoming FDB president & CEO Martin Meeson said Vannais “brings a wealth of experience and demonstrated leadership. Christine will be a key contributor in our continued growth, aligned with our mission to be Partners for Life, advancing tomorrow’s medicines.”

Vannais has over twenty years of experience working in several industries including contract biopharmaceutical development and manufacturing, USDA biological vaccine manufacturing and research, FDA and EU small molecule manufacturing, primary and secondary packaging operations, API potent compound manufacturing, Department of Defense sites, among others.

Both Vannais and Meeson will take up their new roles effective April 1.

FDB has sites in Teesside, UK, Research Triangle Park, North Carolina, College Station, Texas and Hillerod, Denmark.